This inventor holds 1 USPTO granted patent. Top assignee: S O 'Pharmachim'. Active years: 1991.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1991
Title: Yosif N Nisimov: Innovator in Antihypoxic Drug Development
Introduction
Yosif N Nisimov is a notable inventor based in Sofia, Bulgaria. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antihypoxic drugs. His innovative approach has led to the creation of a drug that offers protective effects for the brain and liver.
Latest Patents
Yosif N Nisimov holds a patent for an antihypoxic drug and method of its application. This drug combines piracetam and orotic acid or their pharmaceutically tolerable salts in a specific weight ratio ranging from 500:1 to 1:2. The drug is designed for the treatment of both acute and chronic diseases, as well as exogenic intoxications. It can be administered in daily doses from 0.150 to 50 g and from 0.030 to 0.30 g of both components. Clinical data supports the synergistic effect of this combination in providing antihypoxic action. The drug can be taken orally or parenterally, with oral forms including tablets, capsules, pills, solutions, and emulsions, while parenteral therapy is recommended for severe diseases and acute exogenic intoxications.
Career Highlights
Yosif N Nisimov is associated with S O Pharmachim, where he continues to work on innovative pharmaceutical solutions. His dedication to research and development has positioned him as a key figure in the industry.
Collaborations
Yosif has collaborated with several professionals in his field, including Ani I Genova and Milka P Nikolova. These partnerships have contributed to the advancement of his research and the successful development of his patented drug.
Conclusion
Yosif N Nisimov's work in the field of antihypoxic drugs showcases his commitment to improving medical treatments. His innovative contributions are paving the way for advancements in pharmaceutical applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile